Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents Arthur J. Gallagher in the acquisition of the insurance intermediary Proinova
Mandate

Vinge represents Arthur J. Gallagher in the acquisition of the insurance intermediary Proinova

October 17, 2019 M&A

Arthur J. Gallagher & Co. has acquired the insurance intermediary Proinova as a part of the strategic development and expansion in Scandinavia.

Proinova is an expert within insurance solutions in the real estate segment and offers their services of insurance solutions to both groups and individuals. Vinge has previously represented Arthur J. Gallagher & Co. in the acquisitions of the Swedish insurance intermediaries Brim AB and Nordic Försäkring & Riskhantering AB. 

Vinges team consisted of partner Matthias Pannier with associates Marith Welin‑Berger (M&A), Lisa Ullman, Sophia Holm (employment), Paulina Malmberg (regulatory and financial services), Victor Ericsson (tax) and Hedvig Ekdahl (commercial agreements).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024